Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active crohn's colitis [4]

American Journal of Gastroenterology

Volumn 96, Issue 12, 2001, Pages 3444-3445

  Persley, Kimberly ^a   Scherl, Ellen ^a,b   Rubin, Peter ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MERCAPTOPURINE; STEROID;

ADOLESCENT; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; DRUG USE; HISTOLOGY; HUMAN; IMMUNOMODULATION; LETTER; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035666353     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)03942-9     Document Type: Letter

References (16)

1. Treatment of Crohn's disease with 6MP: Long term, randomized, double-blind study
2. Azathioprine and 6MP in Crohn's disease: A metanalysis
3. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's Disease cA2 Study Group
4. Infliximab for the treatment of fistulas in patients with Crohn's disease
5. National Cooperative Crohn's Disease Study: Results of drug treatment
6. How to do without steroids in inflammatory bowel disease
7. Treatment of fistulizing Crohn's disease
8. Nutritional basis of growth failure in children and adolescents with Crohn's disease
9. Comparison of collagen propeptides as growth markers in children with inflammatory bowel disease
10. The treatment of ulcerative colitis in children with alternate-day corticosteroids
11. Pharmacogenomics and metabolic measurement for 6-mercaptopurine therapy in inflammatory bowel disease
12. A multicenter trial of 6MP and prednisone in children with newly diagnosed Crohn's disease
13. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
14. Maintenance infliximab (Remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the Accent I Trial
15. Tumor necrosis factory a antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
16. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial